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tiveness and cost-beneﬁt of PCV-7 vaccination which
were used to identify and assess additional value deter-
minants speciﬁc to PCV-7. RESULTS: Recent health 
economic evaluations of PCV-7 have resulted in cost-
effectiveness ratios similar to those for currently accepted
health interventions. PCV-7 vaccination would help
Canadians avoid substantial morbidity and mortality and
as a consequence signiﬁcant quantiﬁable healthcare costs
and productivity losses for meningitis, bacteremia, pneu-
monia, otitis media and myringotomy estimated at $63
million. However, the following value health outcomes
and improvements are difﬁcult to quantify in monetary
terms: lives saved, reduced morbidity and costs of treat-
ing other pneumococcal-related diseases, emotional
stresses and improved productivity of parents, the impact
of herd immunity and reduced antimicrobial resistance.
CONCLUSION: Post-licensure studies on changes in the
disease trends and epidemiology of pneumococcal disease
are required to monitor the “real world” impact and
success of a universal PCV-7 vaccination program. Vac-
cination with PCV-7 appears to be a potentially cost-
effective health intervention and may in fact generate
cost-savings when qualitative assessments of value-added
health improvements are considered.
INFECTION—Economic Outcomes
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OBJECTIVE: To evaluate the inﬂuenza vaccination
health (decrease of attack rates of inﬂuenza-like-illness
(ILI)) and economic (work productivity and indirect 
costs avoided) beneﬁts in a company setting, using the
employer perspective. METHODS: A prospective, non-
randomised, non-placebo cost-beneﬁt study was con-
ducted in a petrochemical plant in Malaysia, comparing
2 cohorts: the inﬂuenza vaccinated (volunteers) and not
vaccinated subjects. Inﬂuenza vaccination took place
between 15th March and 15th April 2001 with a follow-
up period of 6 months. Socio-economic and health status
information, data on ILI symptoms and sick leaves were
collected through self-administered monthly question-
naires, whereas vaccines’ adverse events were reported
one week after injection. Immunization beneﬁts were cal-
culated through the avoided absenteeism, itself valued by
replacement costs, individual operating income and
wages. Costs of vaccination covered the vaccine adminis-
tration and its adverse events. Loss of productivity was
assessed by sick leave days and days of reduced effec-
tiveness at work due to being not well because of ILI.
RESULTS: Among the 504 vaccinated and 518 not-
vaccinated subjects, the attack rates of ILI were respec-
tively, 8.13% and 30.31% with presence of fever in
100% of the reported ILI cases. The average length of
sick leave taken for ILI was signiﬁcantly greater in the
not-vaccinated cohort (4.22 ± 1.39 vs 3.00 ± 0.98) as well
as the number of days until feeling well again (5.80 ± 0.85
vs 5.37 ± 0.58). With an effectiveness of 77.98% in avoid-
ing absenteeism, inﬂuenza vaccination lead to a global
cost-savings of US$ 357,955 and a cost-savings of US$
710 per vaccinated employee, when considering the real-
istic hypothesis of a 30% reduced productivity when the
patient is not well because of ILI. CONCLUSIONS:
Inﬂuenza vaccination showed an important effectiveness
in reducing the number of ILI episodes but also indirect
costs, leading to high return on investment for the
employer.
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OBJECTIVE: Inﬂuenza illness rates are high among chil-
dren; they also are a major pathway for disease trans-
mission to adults. Routine vaccination of children against
inﬂuenza therefore may prevent not only their own
illness, but also that of others in the community. The
objective of this study was to estimate the clinical and
economic beneﬁts of such a policy, which are currently
unknown. METHODS: We developed a stochastic simu-
lation model of infection, disease transmission, clinical
illness, and economic costs to assess the population-wide
impact of routinely vaccinating children (ages 1–18 years)
against inﬂuenza. The model depicts the daily interaction
of persons in the population in various “mixing” groups
(e.g., households, playgroups, schools), and simulates the
spread of inﬂuenza infection throughout the community
and the resulting number of illnesses; associated medical
care (direct) and work loss (indirect) costs also are esti-
mated. We used the model to examine the impact of
expanded childhood vaccination (40%, 60%, and 80%
coverage alternatively) versus current practice (5% cov-
erage) on US inﬂuenza-related morbidity, mortality, and
economic costs. In all scenarios, adults were assumed to
receive inﬂuenza vaccine at current US rates. Vaccine efﬁ-
cacy was assumed to be 70%. RESULTS: In the US, there
are currently an estimated 31.5 million cases of inﬂuenza
illness annually, resulting in 119,000 hospitalizations,
11.8 million outpatient visits, $2.3 billion in direct costs,
and $9.5 billion in indirect costs. Routine vaccination of
60% of children would reduce the population-wide
